Rituxan gets expanded US lymphoma indication
This article was originally published in Scrip
The US FDA has approved an additional indication for Roche and Biogen Idec's Rituxan (rituximab) for maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with rituximab plus chemotherapy.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.